DEA Issues Statement on Temporarily Continuing PHE Telehealth Prescribing Flexibilities
The Drug Enforcement Administration (DEA) issued a statement from Administrator Anne Milgram on COVID-19
telehealth flexibilities for prescribing controlled substances. The DEA decided
to temporarily extend the COVID-19 telehealth flexibilities beyond the May 11
end date for the Public Health Emergency (PHE) so that they have more time to
“. . . work to find a way forward to give Americans that access [to telehealth
prescribing] with appropriate safeguards.”
This
decision comes after receiving 38,000 comments in response to two proposed rules
(Telemedicine Prescribing of Controlled Substances When the Practitioner
and the Patient Have Not Had a Prior In-Person Medical Evaluation and
Expansion of Induction of Buprenorphine via Telemedicine Encounter),
which addressed the prescribing of controlled substances based on a telehealth
encounter after the conclusion of the PHE. Advocates complained that the DEA’s
proposals were “more restrictive than is warranted” and would hinder access
to care, particularly for individuals with substance use disorder who started treatment during the PHE.
The proposed regulations would allow for prescribing of a 30-day
supply of “Schedule III-V non-narcotic controlled medications” and “buprenorphine
for the treatment of opioid use disorder” via telehealth with no prior in-person
exam. However, in order to receive more than a 30-day supply, patients who are
receiving prescriptions for non-narcotic controlled medications from a provider
they have never seen in person will need to have at least one in-person appointment
after the public health emergency ends in order to continue receiving their prescriptions.
The temporary rule has not been released yet. However, the
DEA, in conjunction with the Department of Health and Human Services, have submitted
a draft of the “Temporary Extension of COVID-19 Telemedicine Flexibilities for
Prescription of Controlled Medications” to the Office of Management and Budget
for final review prior to publication in the Federal Register.